摘要
目的 研究CD34、CD123抗原和P170蛋白表达与急性髓系白血病（AML）预后的关系.方法 选取2011年10月至2012年10月间在我院治疗AML的患者28例,分别进行化疗,并使用流式细胞仪检测治疗前后的CD34、CD123抗原和P170蛋白表达量,以AML缓解（CR）和未缓解（NR）为指标,对AML的治疗效果进行临床分析,加以统计学比较.结果 难治复发患者的CD34、CD123以及P170的阳性率均高于初治患者,组间差异具有统计学意义（P＜0.05）.当CD34、CD123抗原以及P170蛋白同时为阳性时,NR患者有3例,无CR患者,与其他CR组相比,差异具有统计学意义（P＜0.05）.结论 CD34、CD123抗原以及P170蛋白共表达时,AML的缓解率明显下降,三者的共同表达可以作为AML患者预后的判断指标,为AML患者化疗方案的制定和预后的判断提供一个有价值的依据.
Objective To explore the association of expressions of CD34,CD123,and P170 with prognosis in acute myelocytic leukemia （AML）.Methods 28 patients with AML who had been hospitalized during the period of October 2011 to October 2012 received chemotherapy.Expressions of CD34,CD123,and P170 were detected by flow cytometry before and after treatment.The clinical efficacy of treatment for AML was analyzed and statistically compared by using the indexes of complete remission （CR） and non-remission （NR）.Results The positive rate of CD34,CD123,or P170 was higher in patients with recurrence than patients with primary treatment,with a significant difference between the two groups （P〈0.05）.There were three patients with NR and no one with CR when CD34 and CD123 antigens and P170 protein were simultaneously positive,with a statistical difference （P〈0.05） as compared with other CR groups.Conclusions The rate of complete remission for AML is decreased significantly,when CD34 and CD123 antigens and P170 protein are co-expressed.Co-expression of CD34 and CD123 antigens and P170 protein can be used as a predicting index for prognosis of AML,and provides a valuable support for chemotherapy for AML and for predicting prognosis.
出处
《国际医药卫生导报》
2013年第13期1987-1989,共3页
International Medicine and Health Guidance News
